Clovis oncology, inc. (CLVS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenues:
Product revenue

152,452

143,006

134,050

119,204

109,983

95,388

82,077

76,126

66,989

55,511

0

0

0

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

-

-

-

-

-

-

-

-

-

-

-

-

-

78

0

0

0

0

0

0

0

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

0

License and milestone revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

13,625

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

289,336

283,146

281,883

267,874

249,835

231,347

198,156

173,193

153,594

142,498

158,933

174,347

208,968

251,129

272,670

294,470

287,109

269,251

243,405

202,232

170,304

137,705

110,100

91,198

78,574

66,545

62,285

61,680

58,454

58,894

53,050

49,158

46,247

40,726

0

0

0

Selling, general and administrative

177,606

182,769

186,749

187,433

184,268

175,781

165,156

157,672

148,957

138,907

112,574

86,725

60,128

40,731

36,779

35,948

33,600

30,524

27,891

24,827

22,888

21,457

21,397

20,442

18,669

16,567

13,793

12,243

11,431

10,638

9,903

8,855

7,880

6,860

0

0

0

Acquired in-process research and development

-

9,440

9,440

0

-

0

0

0

0

-

-

-

-

1,300

800

12,300

12,000

12,000

12,000

0

400

8,806

8,806

8,806

8,406

250

250

250

500

4,250

11,250

0

0

-

-

0

-

Other operating expenses

13,160

9,711

5,539

0

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

104,517

194,074

194,074

89,557

89,557

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent purchase consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

24,936

51,818

51,035

24,819

24,611

-407

-512

-609

-707

-2,166

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Total expenses

526,011

519,752

516,104

483,991

460,324

429,202

382,128

347,542

317,131

293,142

280,112

266,779

351,066

372,811

452,505

485,757

397,447

376,721

283,703

227,571

194,201

172,084

146,688

125,943

110,285

83,767

0

0

0

-

-

-

-

-

-

-

-

Operating loss

-373,559

-376,746

-382,054

-364,787

-350,341

-333,814

-300,051

-271,416

-250,142

-237,631

-241,563

-245,036

-343,943

-372,733

-452,505

-485,757

-397,447

-376,721

-283,703

-227,571

-194,201

-158,459

-133,063

-112,318

-96,660

-83,767

-76,328

-74,173

-70,385

-73,782

-67,203

-62,263

-65,127

-54,586

0

0

0

Other income (expense):
Interest expense

25,376

19,405

16,276

14,374

14,138

13,183

12,223

11,465

10,482

10,428

9,970

9,460

8,968

8,491

8,419

8,410

8,401

8,372

8,364

6,776

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency loss

-1,232

-547

-959

-579

-457

-346

11

-184

-4

-82

-273

-295

-188

-580

302

267

-1,058

2,740

3,005

5,429

6,887

3,580

1,973

0

0

0

-

-

0

-

-

-

-

-

-

-

-

Loss on convertible senior notes conversion

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Legal settlement loss

-

-26,750

-26,750

-25,000

-

-27,975

-16,452

-16,452

-113,452

-105,477

-117,000

-117,000

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on extinguishment of debt

-

18,480

18,480

0

-

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

4,783

6,342

7,577

9,332

8,908

7,917

6,824

5,579

4,698

3,643

2,399

1,360

962

633

637

564

430

416

146

-75

-183

-240

-83

14

27

109

54

-49

-188

-228

-629

-1,136

-1,079

-957

0

0

0

Other income (expense), net

-37,886

-21,880

-17,928

-30,621

-25,687

-33,587

-21,840

-22,522

-119,240

-112,344

-124,844

-125,395

-8,194

-8,438

-7,480

-7,579

-9,029

-5,216

-5,213

-1,422

2,025

736

1,277

0

0

0

-

-

0

-

-

-

-

-

-

-

-

Loss before income taxes

-411,445

-398,626

-399,982

-395,408

-376,028

-367,401

-321,891

-293,938

-369,382

-349,975

-366,407

-370,431

-352,137

-381,171

-459,985

-493,336

-406,476

-381,937

-288,916

-228,993

-192,176

-157,723

-131,786

-112,756

-97,401

-84,480

-76,388

-74,336

-70,687

-74,010

-67,832

-63,399

-66,206

-55,543

0

0

0

Income tax benefit

1,890

1,798

202

565

708

608

-1,260

-2,507

-3,755

-3,578

-1,165

-158

-27,936

-32,034

-62,035

-62,436

-33,359

-29,076

-689

231

281

2,308

2,541

0

0

0

-

-

-

-27

0

0

0

0

-

-

-

Net loss

-413,335

-400,424

-400,184

-395,973

-376,736

-368,009

-320,631

-291,431

-365,627

-346,397

-365,242

-370,273

-324,201

-349,137

-397,950

-430,900

-373,117

-352,861

-288,227

-229,224

-192,457

-160,031

-134,327

-115,005

-99,582

-84,532

-76,388

-74,336

-70,652

-73,983

-67,832

-63,399

-66,241

-55,570

0

0

0

Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax

-370

-272

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net unrealized gain on available-for-sale securities, net of tax

44

41

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive (loss) income:

-326

-231

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-413,661

-400,655

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per basic and diluted common share:
Basic and diluted net loss per common share

-1.39

-1.81

-1.72

-2.27

-1.63

-1.88

-1.71

-1.94

-1.54

-1.04

-1.24

-3.88

-1.33

-1.83

-1.70

-3.37

-2.17

-3.12

-2.62

-2.10

-1.86

-1.62

-1.17

-1.03

-0.91

-0.92

-0.68

-0.72

-0.60

-0.81

-0.71

-0.61

-0.86

-1.30

-10.73

-14.32

-6.64

Basic and diluted weighted average common shares outstanding

71,662

54,834

54,707

53,028

52,891

52,724

52,669

52,223

50,602

49,973

48,917

45,176

44,039

38,624

38,538

38,389

38,360

38,321

37,613

34,088

34,011

33,941

33,921

33,872

33,820

31,811

30,047

26,717

26,034

25,948

25,906

25,744

22,041

11,498

1,289

1,292

1,254

Product
Cost of sales

31,617

29,926

28,166

24,798

22,843

19,444

16,594

14,854

13,094

10,251

6,989

3,963

1,233

70

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets amortization
Cost of sales

4,852

4,760

4,327

3,886

3,378

2,630

2,222

1,823

1,486

1,486

1,116

744

372

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-